Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sleep your way to lower blood sugar: study tests personalized sleep extension to prevent diabetes

NCT ID NCT03398902

First seen Jun 25, 2026 · Last updated Jun 25, 2026

Summary

This study tested whether helping adults with pre-diabetes get more sleep could improve their blood sugar control and lower their risk of developing type 2 diabetes. Researchers enrolled 150 people who slept less than 6.5 hours per night and had pre-diabetes. Half were coached to gradually extend their sleep over 8 weeks, while the other half kept their usual sleep habits. The study used continuous glucose monitors to track blood sugar levels before and after the intervention.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREDIABETES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • NYU Langone

    New York, New York, 10010, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

sleep extension (behavioural intervention based on CBTI principles)

What this could lead to

If successful, this approach could offer a simple, drug-free way to lower blood sugar and reduce the risk of developing type 2 diabetes in people with pre-diabetes.

What could go wrong

This is a small, early-stage study with only 150 participants. The intervention is behavioural, so results may vary widely between individuals, and long-term benefits are not yet proven.

Conditions

The condition(s) this trial relates to.

prediabetes syndrome type 2 diabetes mellitus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.